Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (131-140 of 301) with videos related to

Pageof 31
Sort By:
Cancer|January 28, 2003
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastasesJean-Jacques Body, Philip Greipp, Robert E Coleman, et al.
Haematologica|March 1, 2022
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysisFredrik Schjesvold, Paul G Richardson, Thierry Facon, et al.
British Journal of Haematology|August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myelomaRuben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.
European Journal of Haematology|July 24, 2022
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysisIvan Spicka, Philippe Moreau, Thomas G Martin, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 1, 2021
Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With MyelomaJordane Demonchy, Camille Cordier, Emilie Fréalle, et al.
Leukemia & Lymphoma|February 25, 2020
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myelomaMurielle Roussel, Benjamin Hebraud, Cyrille Hulin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trialJean-Luc Harousseau, Michel Attal, Hervé Avet-Loiseau, et al.
Haematologica|December 3, 2011
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trialMartin Kropff, Honorata Giongco Baylon, Jens Hillengass, et al.
Pageof 31

Showing results (131-140 of 301) with videos related to

Sort By:
Pageof 31
Cancer|January 28, 2003
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastasesJean-Jacques Body, Philip Greipp, Robert E Coleman, et al.
Haematologica|March 1, 2022
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysisFredrik Schjesvold, Paul G Richardson, Thierry Facon, et al.
British Journal of Haematology|August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myelomaRuben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.
European Journal of Haematology|July 24, 2022
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysisIvan Spicka, Philippe Moreau, Thomas G Martin, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 1, 2021
Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With MyelomaJordane Demonchy, Camille Cordier, Emilie Fréalle, et al.
Leukemia & Lymphoma|February 25, 2020
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myelomaMurielle Roussel, Benjamin Hebraud, Cyrille Hulin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trialJean-Luc Harousseau, Michel Attal, Hervé Avet-Loiseau, et al.
Haematologica|December 3, 2011
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trialMartin Kropff, Honorata Giongco Baylon, Jens Hillengass, et al.
Pageof 31